CytoDyn Stock Forecast, Price & News

+0.11 (+6.96 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.21 million shs
Average Volume2.07 million shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CYDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter.

CytoDyn logo

About CytoDyn

CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. The company is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. In addition, the company targets leronlimab treatment as a therapy for patients who experience respiratory complications as a result of contracting COVID-19, as well as Leronlimab for the prevention of graft-versus-host disease in patient. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions

Is CytoDyn a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CytoDyn in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CytoDyn stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CYDY, but not buy additional shares or sell existing shares.
View analyst ratings for CytoDyn
or view top-rated stocks.

What stocks does MarketBeat like better than CytoDyn?

Wall Street analysts have given CytoDyn a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CytoDyn wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CytoDyn's next earnings date?

CytoDyn is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for CytoDyn

How were CytoDyn's earnings last quarter?

CytoDyn Inc. (OTCMKTS:CYDY) released its quarterly earnings data on Tuesday, April, 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01.
View CytoDyn's earnings history

How has CytoDyn's stock been impacted by Coronavirus?

CytoDyn's stock was trading at $1.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CYDY shares have increased by 64.1% and is now trading at $1.69.
View which stocks have been most impacted by COVID-19

Who are CytoDyn's key executives?

CytoDyn's management team includes the following people:
  • Dr. Scott A. Kelly, Chairman, Chief Medical Officer & Head of Bus. Devel. (Age 51, Pay $208.22k)
  • Dr. Nader Z. Pourhassan, CEO, Pres & Director (Age 58, Pay $1.53M)
  • Dr. Nitya G. Ray, CTO and Head of Process Sciences, Manufacturing & Supply Chain (Age 68, Pay $563k)
  • Mr. Michael D. Mulholland CPA, CPA, Sr. VP of Fin. (Age 69, Pay $445.43k)
  • Mr. Antonio Migliarese, Chief Financial Officer (Age 38)
  • Dr. Christopher P. Recknor M.D., COO & Head of Clinical Devel.
  • Ms. Arian Colachis J.D., Sr. VP, Gen. Counsel & Corp. Sec. (Age 58)
  • Dr. Brendan P. Rae, Sr. VP of Bus. Devel.
  • Mr. George Bitar, Head of Quality & Exec. Director
  • Dr. Denis R. Burger, Scientific Consultant (Age 77)

Who are some of CytoDyn's key competitors?

What other stocks do shareholders of CytoDyn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Vaxart (VXRT), Nokia (NOK), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Moderna (MRNA).

What is CytoDyn's stock symbol?

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How do I buy shares of CytoDyn?

Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytoDyn's stock price today?

One share of CYDY stock can currently be purchased for approximately $1.69.

How much money does CytoDyn make?

CytoDyn has a market capitalization of $1.05 billion. The biotechnology company earns $-124,400,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

How many employees does CytoDyn have?

CytoDyn employs 19 workers across the globe.

What is CytoDyn's official website?

The official website for CytoDyn is www.cytodyn.com.

Where are CytoDyn's headquarters?

CytoDyn is headquartered at 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660.

How can I contact CytoDyn?

CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected]

This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.